FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022342238> ?p ?o ?g. }

• W2022342238 endingPage "146" @default.
• W2022342238 startingPage "135" @default.
• W2022342238 abstract "Purpose: A multicenter randomized and balanced double-blind trial with the objective of assessing the efficacy and tolerance of nimorazole given as a hypoxic radiosensitizer in conjunction with primary radiotherapy of invasive carcinoma of the supraglottic larynx and pharynx. Patients and treatment: Between January 1986 and September 1990, 422 patients (414 eligible) with pharynx and supraglottic larynx carcinoma were double-blind randomized to receive the hypoxic cell radiosensitizer nimorazole, or placebo, in association with conventional primary radiotherapy (62–68 Gy, 2 Gy per fraction, five fractions per week). The median observation time was 112 months. Results: Univariate analysis showed that the outcome (5-year actuarial loco-regional tumor control) was significantly related to T-classification (T1–T2 48% versus T3–T4 36%, P=0.0008), neck-nodes (N− 53% versus N+ 33%), pre-irradiation hemoglobin (Hb) concentration (high 46% versus low 37%, P=0.02) and sex (females 51% versus males 38%, P=0.03). Overall the nimorazole group showed a significantly better loco-regional control rate than the placebo group (49 versus 33%, P=0.002). A similar significant benefit of nimorazole was observed for the end-points of final loco-regional control (including surgical salvage) and cancer-related deaths (52 versus 41%, P=0.002). This trend was also found in the overall survival but to a lesser, non-significant extent (26 versus 16%, 10-year actuarial values, P=0.32). Cox multivariate regression analysis showed the most important prognostic parameters for loco-regional control to be positive neck nodes (relative risk 1.84 (1.38–2.45)), T3–T4 tumor (relative risk 1.65 (1.25–2.17)) and nimorazole (relative risk 0.69 (0.52–0.90)). The same parameters were also significantly related to the probability of dying from cancer. The compliance to radiotherapy was good and 98% of the patients received the planned dose. Late radiation-related morbidity was observed in 10% of the patients, irrespective of nimorazole treatment. Drug-related side-effects were minor and tolerable with transient nausea and vomiting being the most frequent complications. Conclusion: Nimorazole significantly improves the effect of radiotherapeutic management of supraglottic and pharynx tumors and can be given without major side-effects." @default.
• W2022342238 created "2016-06-24" @default.
• W2022342238 creator A5026616819 @default.
• W2022342238 creator A5027700393 @default.
• W2022342238 creator A5042502392 @default.
• W2022342238 creator A5057277696 @default.
• W2022342238 creator A5073129301 @default.
• W2022342238 creator A5080417921 @default.
• W2022342238 creator A5080454503 @default.
• W2022342238 creator A5083034892 @default.
• W2022342238 date "1998-02-01" @default.
• W2022342238 modified "2023-10-11" @default.
• W2022342238 title "A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85" @default.
• W2022342238 cites W1964437446 @default.
• W2022342238 cites W1968286944 @default.
• W2022342238 cites W1977660331 @default.
• W2022342238 cites W1993019230 @default.
• W2022342238 cites W1997112823 @default.
• W2022342238 cites W2001860947 @default.
• W2022342238 cites W2007022307 @default.
• W2022342238 cites W2013729607 @default.
• W2022342238 cites W2013839767 @default.
• W2022342238 cites W2021424740 @default.
• W2022342238 cites W2027944612 @default.
• W2022342238 cites W2044547528 @default.
• W2022342238 cites W2045116905 @default.
• W2022342238 cites W2048089152 @default.
• W2022342238 cites W2048544046 @default.
• W2022342238 cites W2050315089 @default.
• W2022342238 cites W2053549859 @default.
• W2022342238 cites W2059376449 @default.
• W2022342238 cites W2063923447 @default.
• W2022342238 cites W2064741964 @default.
• W2022342238 cites W2067538700 @default.
• W2022342238 cites W2073286608 @default.
• W2022342238 cites W2073304281 @default.
• W2022342238 cites W2074308841 @default.
• W2022342238 cites W2080141853 @default.
• W2022342238 cites W2082943253 @default.
• W2022342238 cites W2085409346 @default.
• W2022342238 cites W2087604644 @default.
• W2022342238 cites W2087704303 @default.
• W2022342238 cites W2090896110 @default.
• W2022342238 cites W2093596753 @default.
• W2022342238 cites W2097874838 @default.
• W2022342238 cites W2118170166 @default.
• W2022342238 cites W2124376738 @default.
• W2022342238 cites W2124760546 @default.
• W2022342238 cites W2131292435 @default.
• W2022342238 cites W2134541707 @default.
• W2022342238 cites W2153965661 @default.
• W2022342238 cites W2155547052 @default.
• W2022342238 cites W2616852889 @default.
• W2022342238 cites W4232698275 @default.
• W2022342238 doi "https://doi.org/10.1016/s0167-8140(97)00220-x" @default.
• W2022342238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9925257" @default.
• W2022342238 hasPublicationYear "1998" @default.
• W2022342238 type Work @default.
• W2022342238 sameAs 2022342238 @default.
• W2022342238 citedByCount "495" @default.
• W2022342238 countsByYear W20223422382012 @default.
• W2022342238 countsByYear W20223422382013 @default.
• W2022342238 countsByYear W20223422382014 @default.
• W2022342238 countsByYear W20223422382015 @default.
• W2022342238 countsByYear W20223422382016 @default.
• W2022342238 countsByYear W20223422382017 @default.
• W2022342238 countsByYear W20223422382018 @default.
• W2022342238 countsByYear W20223422382019 @default.
• W2022342238 countsByYear W20223422382020 @default.
• W2022342238 countsByYear W20223422382021 @default.
• W2022342238 countsByYear W20223422382022 @default.
• W2022342238 countsByYear W20223422382023 @default.
• W2022342238 crossrefType "journal-article" @default.
• W2022342238 hasAuthorship W2022342238A5026616819 @default.
• W2022342238 hasAuthorship W2022342238A5027700393 @default.
• W2022342238 hasAuthorship W2022342238A5042502392 @default.
• W2022342238 hasAuthorship W2022342238A5057277696 @default.
• W2022342238 hasAuthorship W2022342238A5073129301 @default.
• W2022342238 hasAuthorship W2022342238A5080417921 @default.
• W2022342238 hasAuthorship W2022342238A5080454503 @default.
• W2022342238 hasAuthorship W2022342238A5083034892 @default.
• W2022342238 hasConcept C126322002 @default.
• W2022342238 hasConcept C141071460 @default.
• W2022342238 hasConcept C142724271 @default.
• W2022342238 hasConcept C143998085 @default.
• W2022342238 hasConcept C144301174 @default.
• W2022342238 hasConcept C204787440 @default.
• W2022342238 hasConcept C27081682 @default.
• W2022342238 hasConcept C2776428644 @default.
• W2022342238 hasConcept C2776530083 @default.
• W2022342238 hasConcept C2776752453 @default.
• W2022342238 hasConcept C2777546739 @default.
• W2022342238 hasConcept C2778424827 @default.
• W2022342238 hasConcept C2780474809 @default.
• W2022342238 hasConcept C38180746 @default.
• W2022342238 hasConcept C509974204 @default.
• W2022342238 hasConcept C71924100 @default.
• W2022342238 hasConceptScore W2022342238C126322002 @default.

• next